share_log

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

NKGen Biotech 在 2024 年美国临床肿瘤学会 (ASCO) 年会上发布了晚期实体瘤中 SNK02 异基因 NK 细胞疗法的 1 期中期分析结果
GlobeNewswire ·  05/24 05:05

SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens with immune checkpoint inhibitors.

SNK02 有可能成为首创的针对实体瘤的冷冻保存异体 NK 细胞疗法,这种疗法在给药前不需要淋巴消耗,这可能会改善未来与免疫检查点抑制剂联合疗法的整体协同作用。

In this Phase 1 trial, the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02.

在这项 1 期试验中,在完成 8 个 SNK02 治疗周期的患者中,100% 的患者证实了稳定疾病的最佳客观反应。

SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion.

SNK02 作为单一疗法具有良好的耐受性,尽管没有淋巴消耗,但似乎对预先治疗的实体瘤具有一定的临床活性。

SANTA ANA, Calif., May  23, 2024  (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced an online publication, titled "Interim Analysis of a Phase I Study using Cryopreserved Non-genetically Modified Allogeneic Natural Killer Cells With Enhanced Cytotoxicity (SNK02) in Patients with Advanced Solid Tumors without Lymphodepletion" at the 2024 American Society of Clinical Oncology ("ASCO") Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

加利福尼亚州圣安娜,2024年5月23日(GLOBE NEWSWIRE)——专注于创新自体、异基因和CAR-NK自然杀伤(“NK”)细胞疗法开发和商业化的临床阶段生物技术公司 NKGen Biotech, Inc.(纳斯达克股票代码:NKGN)(“NKGen” 或 “公司”)今天宣布了一份在线出版物,名为 “中期分析” 使用冷冻保存的具有增强细胞毒性(SNK02)的非基因改造异基因自然杀伤细胞(),用于 2024 年 “无淋巴消耗的晚期实体瘤患者” 的 I 期研究美国临床肿瘤学会(“ASCO”)年会将于 2024 年 5 月 31 日至 6 月 4 日在伊利诺伊州芝加哥的味好美广场会议中心以虚拟方式举行。

This Phase 1 clinical trial is a multi-center, open-label study evaluating the safety and tolerability of SNK02 in participants with pathologically confirmed solid tumors refractory to standard of care therapy. The study drug, SNK02, is a first-in-kind, cryopreserved allogeneic non-genetically modified NK cell product with significant anti-tumor cytotoxicity and over 90% expression of CD16, NKG2D, NKp46, and DNAM-1, that can be consistently produced on a large commercial scale. SNK02 was administered as an intravenous infusion (IV), weekly for eight weeks in patients with advanced solid tumors. The starting dose was 6x109 SNK02 cells. We hypothesized that higher doses of SNK02 (to overcome autodigestion) could be delivered frequently without the need for lymphodepletion and that it might demonstrate activity against solid tumors that have failed multiple prior standard-of-care treatment options. The primary endpoint was safety based on adverse events (AEs), vitals, laboratory tests, and physical exams. Tolerability of SNK02 and maximum tolerated dose were also evaluated.

这项 1 期临床试验是一项多中心、开放标签的研究,评估 SNK02 对经病理证实且不符合标准护理疗法的实体瘤的参与者的安全性和耐受性。该研究药物 SNK02 是同类首创、冷冻保存的非转基因非转基因 NK 细胞产物,具有显著的抗肿瘤细胞毒性,CD16、NKG2D、nkp46 和 DNAM-1 的表达量超过 90%,可以在大规模商业规模上持续生产。对于晚期实体瘤患者,SNK02 以静脉输注(IV)的形式给药,持续八周。起始剂量为 6x109 个 SNK02 细胞。我们假设,无需淋巴消耗即可频繁输送更高剂量的 SNK02(以克服自身消化),并且它可能显示出对先前多种标准护理治疗方案失败的实体瘤的活性。主要终点是基于不良事件 (AE)、生命体征、实验室测试和体格检查的安全性。还评估了 SNK02 的耐受性和最大耐受剂量。

"Interim data from our Phase 1 clinical study utilizing our second NK cell therapy product, SNK02, demonstrated that the treatment was well-tolerated as a monotherapy in patients with solid tumors refractory to standard of care therapy," said Paul Y. Song, MD, Chairman and CEO of NKGen. "We are particularly excited because SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall synergy in future combination regimens especially with immune checkpoint inhibitors where a robust T-cell response is needed. Using our proprietary allogeneic manufacturing and cryopreservation processes, we are capable of producing hundreds of thousands of potential doses of enhanced NK cell therapies from materials collected from a single donor. Thus, our potential to treat a significant number of cancer patients with SNK02 is remarkably high. We are pleased to see such promising Phase 1 trial results for both of our unique cell therapy candidates: autologous SNK01 for neurodegenerative disease and allogeneic SNK02 for cancer."

NKGen董事长兼首席执行官Paul Y. Song医学博士表示:“我们使用我们的第二款NK细胞疗法产品 SNK02 进行的1期临床研究的中期数据表明,该疗法作为单一疗法对标准护理疗法难治的实体瘤患者具有良好的耐受性。”“我们特别兴奋,因为 SNK02 有可能成为首创的针对实体瘤的冷冻保存同种异体 NK 细胞疗法,这种疗法在给药前不需要淋巴消耗,这可能会在未来的联合方案中带来更好的整体协同作用,尤其是需要强大 T 细胞反应的免疫检查点抑制剂。使用我们专有的同种异体制造和冷冻保存工艺,我们能够利用从单个捐赠者那里收集的材料生产数十万种潜在剂量的增强型 NK 细胞疗法。因此,我们用 SNK02 治疗大量癌症患者的潜力非常高。我们很高兴看到我们两种独特的候选细胞疗法的1期试验结果如此令人鼓舞:用于神经退行性疾病的自体 SNK01 和用于癌症的异基因 SNK02。”

For additional information on the SNK02 clinical trial, please visit  using the identifier NCT05990920.

有关 SNK02 临床试验的更多信息,请使用标识符 NCT05990920 访问。

Highlights from the online publication include:

在线出版物的亮点包括:

  • Five patients with advanced refractory solid tumors were enrolled in the trial.

  • Patients had received an average of 4 lines of prior therapy.

  • Median age was 64 (range 44 – 71) and 3 were male.

  • The subtypes were 1 leiomyosarcoma, 1 angiosarcoma, 1 endometrial adenocarcinoma, 1 undifferentiated pleomorphic sarcoma, and 1 colorectal adenocarcinoma.

  • Four of five patients completed 8 cycles of SNK02. The best objective response of stable disease (tumor stopped growing) was demonstrated in 100% of patients that completed the 8 cycles.

  • Out of the 36 doses administered through Cycle 8, there were 17 Grade 1, 3 Grade 2, and 1 Grade 3 adverse events (AEs) related to investigational product (IP). The Grade 3 AE of increased fatigue resolved after 1 day with no intervention required.

  • There was 1 death on study, which was deemed unrelated to the IP.

  • Auto-antibodies appeared to develop around cycle 5 and appeared to correlate with AEs.

  • SNK02 was well tolerated as a monotherapy and appears to have some clinical activity against pretreated solid tumors despite the lack of lymphodepletion. SNK02 will continue to be studied as a monotherapy and in potential combination treatment regimens with monoclonal antibodies and immune checkpoint inhibitors.

  • 该试验招收了五名晚期难治性实体瘤患者。

  • 患者先前平均接受了4线治疗。

  • 中位年龄为64岁(范围在44-71岁之间),其中3人为男性。

  • 亚型为 1 种平滑肌肉瘤、1 种血管肉瘤、1 种子宫内膜腺癌、1 种未分化多形肉瘤和 1 种结直肠腺癌。

  • 五名患者中有四名完成了 SNK02 的 8 个周期。在完成8个周期的患者中,100%显示了稳定疾病(肿瘤停止生长)的最佳客观反应。

  • 在第8周期给药的36剂中,有17种与研究产品(IP)相关的1级、3种2级和1种3级不良事件(AE)。3 级疲劳加剧症状在 1 天后缓解,无需干预。

  • 研究中有1人死亡,被认为与知识产权无关。

  • 自身抗体似乎在周期5前后形成,似乎与不良反应相关。

  • SNK02 作为单一疗法具有良好的耐受性,尽管没有淋巴消耗,但似乎对预先治疗的实体瘤具有一定的临床活性。SNK02 将继续作为单一疗法和潜在的单克隆抗体和免疫检查点抑制剂联合治疗方案进行研究。

A copy of the ePublication will be available on the Scientific Publications page of the Company's website

电子出版物的副本将在公司网站的科学出版物页面上公布

About SNK02

关于 SNK02

SNK02 is a novel cell-based, donor-derived ex vivo expanded allogeneic natural killer ("NK") cell, immunotherapeutic drug candidate. NKGen Biotech, Inc. is developing SNK02 for the treatment of a broad range of cancers.

SNK02 是一种新型的基于细胞、由捐赠者衍生的体外扩增异基因自然杀伤(“NK”)细胞,是免疫治疗候选药物。NKGen Biotech, Inc. 正在开发 SNK02,用于治疗各种癌症。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发